on SARTORIUS STED BIO (EPA:DIM)
Half-year review of the Sartorius Stedim Biotech liquidity contract
As of June 30, 2024, the liquidity contract of Sartorius Stedim Biotech, managed by Kepler Cheuvreux, displays 46,292 securities and €2,521,189.91 in cash. Purchase transactions accounted for 6,493 operations for 305,402 securities, or €69,412,550.00. Those for sale total 5,322 operations for 273,281 securities, or €63,664,027.43.
As of the last balance sheet in December 2023, Sartorius Stedim Biotech held 14,171 shares and €8,132,662.14 in cash. The operations included 5,238 purchases for 230,377 securities, or €50,832,014.40, and 4,912 sales for 239,123 securities, or €54,101,099.12.
The initial liquidity contract, for its part, did not include any securities but had €10,000,000.00 in cash. This assessment is in accordance with AMF decision no. 2021-01.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news